【摘要】 目的:探索血清S100B蛋白表达水平对于小细胞肺癌(Small Cell Lung Cancer,SCLC)患者脑转移风险的预测价值以及与SCLC患者临床病理特征的关系。方法:选择20例脑转移SCLC患者和24例无脑转移SCLC患者,同时纳入16例术后SCLC患者作为对照组。使用免疫酶吸附法(Enzyme Linked Immunosorbent Assay Kit,ELISA)检测三组患者血清S100B蛋白的表达水平。结果:与SCLC无脑转移患者和术后SCLC对照组相比,SCLC脑转移患者血清S100B蛋白水平均明显升高(均P<0.001)。受试者工作特征曲线(Receiver Operating Characteristic,ROC)表明血清S100B蛋白水平对SCLC患者脑转移风险具有较高的预测价值(SCLC脑转移患者组vs.SCLC无脑转移患者组:曲线下面积(Area Under Curve,AUC)0.840(95%CI:0.721~0.958);SCLC脑转移患者组vs.术后SCLC对照组:AUC 0.906(95%CI:0.811~1.000))。单元、多元逻辑回归分析显示,高水平血清S100B蛋白是SCLC患者脑转移风险的独立预测因素(P=0.025)。此外,在SCLC脑转移患者组中,血清S100B水平与N分期呈正相关(P=0.019)。Spearman秩相关分析显示在SCLC脑转移患者中血清S100B蛋白水平与神经元特异性烯醇化酶(Neuron Specific Enolase,NSE)呈正相关(r=0.508,P=0.022)。结论:血清S100B蛋白水平具有作为预测SCLC患者脑转移风险血清学标志物的潜能,且与SCLC脑转移患者N分期和血清NSE水平呈正相关。更多还原

【Abstract】 Objective: To evaluate the predictive value of serum S100 B expression in brain metastasis risk for patients with small cell lung cancer(SCLC) and its association with clinicopathological characteristics of SCLC patients. Methods: 20 SCLC patients with brain metastases,24 SCLC patients without brain metastases and 16 post-operative SCLC patients as control group were enrolled in this case-control study. The serum levels of S100 B in three groups were detected by ELISA. Results: Serum S100 B levels in SCLC patients with brain metastases were markedly increased compared with SCLC patients without brain metastasis and postoperative SCLC patients(all P <0.001). Receiver Operating Characteristic(ROC) showed that serum S100 B level had a good predictive value for brain metastasis in SCLC patients(SCLC patients with brain metastases vs.SCLC patients without brain metastases: AUC 0.840(95% CI: 0.721 ~ 0.958); SCLC patients with brain metastases vs. post-operative SCLC patients: AUC 0.906(95% CI: 0.811 ~ 1.000)). Multivariate regression analysis displayed that high level of serum S100 B was an independent factor in predicting brain metastasis risk in SCLC patients(P = 0.025). In addition,serum S100 B level was positive associated with N stage in SCLC patients with brain metastases(P = 0.019). Spearman rank correlation analysis revealed that serum S100 B level was positively correlated with Neuron Specific Enolase(NSE) in SCLC patients with brain metastases(r =0.508,P = 0. 022). Conclusion: Serum S100 B could be a promising biomarker of brain metastasis risk in SCLC patients,and it is positively correlated with N stage and NSE level in SCLC patients with brain metastasis.更多还原